Jeudi 1 juillet 2021 - Mis à jour le Vendredi 2 juillet 2021

Ebola vaccines


The study, "An open-label, single arm study to provide additional information on immunogenicity and safety of Ad26.ZEBOV/MVA-BN®-Filo" is an interventional, single arm, open-label, non-randomized, phase II study to accumulate additional data on immunogenicity and safety of the two vaccines Ad26.ZEBOV/MVA-BN®-Filo against Ebola virus disease. The primary objective is to to assess the humoral immune responses as measured by enzyme-linked immunosorbent assay (ELISA) to the Ebola glycoprotein after intramuscular administration of the vaccine in all participants. Safety, serious adverse event reporting and follow-up on outcomes of pregnancy, is the second primary objectives of this study.




Tentative End date

December 2021

Our Role

Scientific Oversight, Study Site



The purpose of this study, "evaluation of the field efficacy and safety of a two-dose heterologous Ebola prophylaxis vaccine in the Democratic Republic of Congo", is to vaccinate with one of the candidate vaccines, VAC52150 (Ad26. ZEBOV, MVA-BN®-Filo), in order to determine the field efficacy of the vaccine regimen to prevent EVD through a case-control (test-negative) study and to document the activities related to the implementation of a two-dose regimen in this setting. This study is an open, nonrandomized study of the Ad26.ZEBOV/MVA-BN-Filo vaccine regimen in a population of eligible adults and children. The objective is to estimate the field efficacy of vaccination of the population with the Ad26.ZEBOV / MVA-BN-Filo vaccination regimen for the prevention of EVD in adults and children at least 1 year of age.



Democratic Republic of Congo

Tentative End date

February 2022

Our Role

Scientific Oversight, Data, Management, Monitoring and PV, Capacity Building


for more information contact: Rebecca Grais